Esperion Therapeutics, Inc. develops and markets medical devices. The Company produces oral, small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors.

Current Report (Form 8-K | Period ending 2024-12-17)

Current Report (Form 8-K | Period ending 2024-12-12)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Esperion Therapeutics (ESPR US)

Current Report (Form 8-K | Period ending 2024-12-17)

Current Report (Form 8-K | Period ending 2024-12-12)

Current Report (Form 8-K | Period ending 2024-11-07)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)